Literature DB >> 25212890

Immunotherapy strategies in multiple myeloma.

Jooeun Bae1, Nikhil C Munshi2, Kenneth C Anderson2.   

Abstract

Multiple myeloma (MM) is a B-cell malignancy characterized by the clonal proliferation of malignant plasma cells in the bone marrow and the development of osteolytic bone lesions. MM has emerged as a paradigm within the cancers for the success of drug discovery and translational medicine. This article discusses immunotherapy as an encouraging option for the goal of inducing effective and long-lasting therapeutic outcome. Divided into two distinct approaches, passive or active, immunotherapy, which targets tumor-associated antigens has shown promising results in multiple preclinical and clinical studies.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Active-specific immunotherapy; Multiple myeloma; Passive-specific immunotherapy

Mesh:

Substances:

Year:  2014        PMID: 25212890     DOI: 10.1016/j.hoc.2014.07.002

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  7 in total

1.  Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy.

Authors:  Jooeun Bae; Mehmet Samur; Paul Richardson; Nikhil C Munshi; Kenneth C Anderson
Journal:  Leukemia       Date:  2019-03-12       Impact factor: 11.528

2.  MMSA-1 expression pattern in multiple myeloma and its clinical significance.

Authors:  Shan Meng; Chenyang Lu; Wanggang Zhang; Wenjun Shen; Yongchang Wei; Dan Su; Fuling Zhou
Journal:  Clin Exp Med       Date:  2015-10-22       Impact factor: 3.984

3.  Improved response rates with bortezomib in relapsed or refractory multiple myeloma: an observational study in Chinese patients.

Authors:  MaoFang Lin; Jian Hou; WenMing Chen; XiaoJun Huang; ZhuoGang Liu; YuHong Zhou; Yan Li; Taiyun Zhao; LinNa Wang; Kwang-Wei Wu; ZhiXiang Shen
Journal:  Adv Ther       Date:  2014-10-21       Impact factor: 3.845

4.  Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma.

Authors:  Shang-Yi Huang; Tsai-Yun Chen; Ching-Yuan Kuo; Yeu-Chin Chen; Sheng-Fung Lin; Ming-Chih Chang; Xinzhu Lv; Betty Yang; Cheng-Shyong Chang
Journal:  Oncol Rev       Date:  2019-01-18

5.  Cytotoxic T Cell Responses Induced by CS1/CRT Fusion DNA Vaccine in a Human Plasmacytoma Model.

Authors:  Xueshi Ye; Wanli Li; Jinwen Huang; Lifei Zhang; Ye Zhang
Journal:  Front Oncol       Date:  2020-11-20       Impact factor: 6.244

Review 6.  Immunotherapy in Multiple Myeloma Using Cancer-Testis Antigens.

Authors:  Soudeh Ghafouri-Fard; Mahnaz Seifi-Alan; Roshanak Shamsi; Ali Esfandiary
Journal:  Iran J Cancer Prev       Date:  2015-10-27

7.  Bone marrow IRF4 level in multiple myeloma: an indicator of peripheral blood Th17 and disease.

Authors:  Hua Bai; Shuang Wu; Rong Wang; Ji Xu; Lijuan Chen
Journal:  Oncotarget       Date:  2017-08-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.